Skip to content
Catalyst

knowcompoundsfolic acid

Specimen compound organic compoundPlate I

Folic acid

Nested hairline contours trace the electron density of one computed shape of folic acid, teal at the edge warming to amber over the atoms.
fig. 1Folic acid · electron density · PubChem CID 135398658, computed 3D conformer
Formula
C19H19N7O6
Molar mass
441.404 g/mol
PubChem CID
135398658
InChIKey
OVBPIULPVIDEAO-LBPRGKRZSA-N

↑ raised 3 findings in 3 endpoints · ↓ lowered 6 in 6 · – no difference found 13 in 11

01 · the evidence, ordered

What the evidence says

Strong
0
Moderate
13
Limited
1
Very limited
8
Insufficient
0

How to read these marks

Fig. 2 Folic acid CHEBI:27470 18 endpoints 22 findings
×1.60
Labels
CompoundInspector

Folic acid

Most findings

  • All-site cancer incidence×2
  • Colorectal adenoma recurrence after polypectomy×2
  • Colorectal cancer incidence×2
  • Preterm birth incidence×2
Show the remaining 14Show the first 4
  • All-cause mortality×1
  • Autism spectrum disorder diagnosis (offspring)×1
  • C-reactive protein concentration×1
  • Fasting blood glucose×1
  • Forced expiratory volume in one second (FEV1)×1
  • Gestational age at delivery (length of gestation)×1
  • Gestational hypertension incidence×1
  • Incidence of cardiovascular disease (composite)×1
  • Interleukin-6 concentration×1
  • Lung cancer incidence×1
  • Mean arterial pressure×1
  • Mini-Mental State Examination total score×1
  • Montreal Cognitive Assessment total score×1
  • Pre-eclampsia incidence×1

31 reference statements, not drawn · 36 compounds on the outer ring, not drawn

Keys

← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it

  1. All-site cancer incidencecontested
  2. Colorectal cancer incidence
  3. Preterm birth incidence
  4. All-cause mortality
  5. Autism spectrum disorder diagnosis (offspring)
  6. C-reactive protein concentration
  7. Fasting blood glucose
  8. Forced expiratory volume in one second (FEV1)
  9. Gestational age at delivery (length of gestation)
  10. Interleukin-6 concentration
  11. Lung cancer incidence
  12. Mini-Mental State Examination total score
  13. Montreal Cognitive Assessment total score
  14. Colorectal adenoma recurrence after polypectomycontested
  15. Gestational hypertension incidence
  16. Incidence of cardiovascular disease (composite)
  17. Mean arterial pressure
  18. Pre-eclampsia incidence
Show the remaining 10Show the first 8
fig. 3 · 18 endpoints · 22 findingscontested · an endpoint whose findings disagree

02 · contested · 2 endpoints

Where the findings disagree

  1. 012 findings

    All-site cancer incidence

    – no difference found
    1
    ↑ raised
    1
  2. 022 findings

    Colorectal adenoma recurrence after polypectomy

    ↓ lowered
    1
    – no difference found
    1

03 · findings

What folic acid moved, and by how much

  • OR odds ratio · RR risk ratio · HR hazard ratio · SMD standardised mean difference · MD mean difference. Brackets: the interval as reported.
  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed
  • Industry funding: named on its row.
Direction
Strength, at least

12 of 22 shown

  1. Forced expiratory volume in one second (FEV1)Moved: no difference foundEvidence: ModeratePaper: PMID 288846032018
    Who
    Children aged 7 to 10 years at the mid-childhood visit in the Project Viva prospective birth cohort (Massachusetts), by maternal first-trimester folic acid intake from food and supplements (quartiles); whole cohort, not sex-stratified
    Dose studied
    maternal intake from food plus supplements, FFQ, quartiles

    There was no association between maternal folic acid intake and post-FEV1 in the total cohort of children.”

    Quoted verbatim from Folic Acid in Pregnancy and Childhood Asthma: A US Cohort.cohortPermalink
  2. Autism spectrum disorder diagnosis (offspring)Moved: lowersEffect, as reportedOR0.66[0.55 to 0.79]Evidence: ModeratePaper: PMID 412285122025
    Who
    Offspring of mothers who did or did not take folic acid before and/or during pregnancy, pooled from 24 non-randomised studies (case-control, cohort and cross-sectional)
    Dose studied
    not reported

    The MA indicated that maternal folic acid supplementation is associated with a significant reduction in the risk of offspring ASD (pooled OR = 0.66, 95% CI: 0.55–0.79), as shown in the forest plot.”

    Quoted verbatim from The Effect of Maternal Folic Acid Supplementation on Neurodevelopmental Disorders in Offspring: An Umbrella Review of Systematic Reviews and Meta-Analyses.meta-analysisPermalink
  3. Montreal Cognitive Assessment total scoreMoved: raisesEvidence: ModeratePaper: PMID 409459662026
    Who
    Adults aged 40-80 years with cerebral small vessel disease-related cognitive impairment, intention-to-treat analysis at 6 months
    Dose studied
    0.4 mg tablet, two tablets daily, six months

    Specifically, total MoCA score (ITT: β = 1.27; 95 % CI = 0.52, 2.03; PP: β = 1.15; 95 % CI = 0.37, 1.93) and total MMSE score (ITT: β = 0.76; 95 % CI = 0.14, 1.39; PP: β = 0.65; 95 % CI = 0.02, 1.28) were improved among patients with CSVD-CI in the FA intervention group compared with those in the placebo group at follow-ups after adjustment of potential confounders.”

    Quoted verbatim from Folic acid supplementation improves cognitive function in participants with cerebral small vascular disease-related cognitive impairment: a randomized controlled trial.RCTPermalink
  4. Mini-Mental State Examination total scoreMoved: raisesEvidence: ModeratePaper: PMID 409459662026
    Who
    Adults aged 40-80 years with cerebral small vessel disease-related cognitive impairment, intention-to-treat analysis at 6 months
    Dose studied
    0.4 mg tablet, two tablets daily, six months

    Specifically, total MoCA score (ITT: β = 1.27; 95 % CI = 0.52, 2.03; PP: β = 1.15; 95 % CI = 0.37, 1.93) and total MMSE score (ITT: β = 0.76; 95 % CI = 0.14, 1.39; PP: β = 0.65; 95 % CI = 0.02, 1.28) were improved among patients with CSVD-CI in the FA intervention group compared with those in the placebo group at follow-ups after adjustment of potential confounders.”

    Quoted verbatim from Folic acid supplementation improves cognitive function in participants with cerebral small vascular disease-related cognitive impairment: a randomized controlled trial.RCTPermalink
  5. Colorectal cancer incidenceMoved: no difference foundEffect, as reportedRR1[0.82 to 1.22]Evidence: Moderatereplicated ×1Paper: PMID 261317632015
    Who
    Participants in eight randomized controlled trials of folic acid, total population
    Dose studied
    not reported

    The results suggested that folic acid treatment was not associated with colorectal cancer risk in the total population (relative risk [RR] = 1.00, 95% confidence interval [CI] = 0.82-1.22, P = 0.974).”

    Quoted verbatim from Folic acid supplements and colorectal cancer risk: meta-analysis of randomized controlled trials.meta-analysisPermalink
  6. Preterm birth incidenceMoved: no difference foundEvidence: Moderatereplicated ×1Paper: PMID 355775772022An author is affiliated with a producer
    Who
    Norwegian MoBa cohort pregnancies of women with epilepsy not using antiseizure medication, and of women without epilepsy; periconceptional folic acid use versus none
    Dose studied
    not reported

    We found no association between folic acid supplement and preterm birth in the Epilepsy without ASM group or in the No epilepsy group (Table 2).”

    Quoted verbatim from Folic Acid and Risk of Preterm Birth, Preeclampsia, and Fetal Growth Restriction Among Women With Epilepsy: A Prospective Cohort Study.cohortPermalink
  7. All-site cancer incidencecontestedMoved: no difference foundEffect, as reportedRR1.06[0.99 to 1.13]Evidence: ModeratePaper: PMID 233525522013An author is affiliated with a producer
    Who
    Adults in 13 randomised trials of folic acid versus placebo (10 trials in people with or at high risk of cardiovascular disease, 3 in patients with prior colorectal adenoma); mean age 64 years
    Dose studied
    0.5 to 5 mg folic acid daily in all trials but one (40 mg daily); one trial compared 2.5 mg with 0.02 mg

    Allocation to folic acid treatment did not have any statistically significant effect on overall cancer incidence, with 1904 (7.7%) first events in 24,799 participants allocated folic acid versus 1809 (7.3%) in 24,822 allocated control (RR 1.06; 95% CI 0.99–1.13, p=0.10: Figure 1).”

    Quoted verbatim from Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals.meta-analysisPermalink
  8. All-cause mortalityMoved: no difference foundEvidence: ModeratePaper: PMID 364324342022
    Who
    1553 postmenopausal women in the Women's Health Initiative diagnosed with invasive breast cancer, who completed a food frequency questionnaire before and after diagnosis; change in dietary folate/folic acid intake from before to after diagnosis, mean follow-up 16.1 years
    Dose studied
    not reported

    Furthermore, changes in dietary folate/folic acid or vitamin B12 intake were not associated with all-cause or breast cancer mortality after adjustment of other prognostic and dietary factors (Table 2 and Table 3).”

    Quoted verbatim from Changes in Dietary Intake of Methionine, Folate/Folic Acid and Vitamin B12 and Survival in Postmenopausal Women with Breast Cancer: A Prospective Cohort Study.cohortPermalink
  9. Lung cancer incidenceMoved: no difference foundEffect, as reportedHR1.09[0.91 to 1.3]Evidence: ModeratePaper: PMID 308384352020
    Who
    Black and white adults aged 40-79 in the Southern Community Cohort Study, southeastern US; dietary intake of synthetic folic acid from foods (fortification), highest vs lowest quartile, fully-adjusted model
    Dose studied
    dietary food folic acid intake per 1,000 kcal, highest vs lowest quartile (FFQ)

    When we further investigated natural dietary folate (“food folate”) and synthetic folic acid (“food folic acid”) intakes from foods separately (Table 4), neither of them were associated with lung cancer risk (food folate: HR=1.00, 95% CI=0.84–1.19, P-trend=0.79; food folic acid: HR=1.09, 95% CI=0.91–1.30, P-trend=0.44).”

    Quoted verbatim from Food intake of folate, folic acid and other B vitamins with lung cancer risk in a low-income population in the Southeastern United States.cohortPermalink
  10. Gestational age at delivery (length of gestation)Moved: no difference foundEvidence: ModeratePaper: PMID 387834132024Industry funded
    Who
    Pregnant women in South Australia randomised at 12-16 weeks gestation to a prenatal multivitamin and mineral supplement with 800 µg/day folic acid or the same formulation without folic acid, until 36 weeks; multivitamin and mineral content identical in both arms
    Dose studied
    800 µg/day folic acid versus 0 µg/day, in a prenatal multivitamin and mineral supplement

    There were no significant differences between the groups for birth gestational age, weight and length, except for head circumference, which was lower in the 0 µg FA/day supplement group compared to the 800 µg FA/day group (mean difference: −0.9 cm; 95% CI, −1.8, −0.1, p = 0.04) (Table 2).”

    Quoted verbatim from Maternal serum unmetabolized folic acid concentration following multivitamin and mineral supplementation with or without folic acid after 12 weeks gestation: A randomized controlled trial.RCTPermalink
  11. Interleukin-6 concentrationMoved: no difference foundEffect, as reportedSMD−0.04[−1.08 to 1.01]Evidence: ModeratePaper: PMID 386493472024
    Who
    Adults with type 2 diabetes mellitus; two randomized placebo-controlled trials pooled for IL-6
    Dose studied
    not reported

    Only two trials assessed the effect of folate on IL-6; the evidence from the random-effect meta-analysis showed a small effect size, and this also not significant, SMD = −0.04, 95%CI (−1.08, 1.01), p = 0.95.”

    Quoted verbatim from Folic acid supplementation on inflammation and homocysteine in type 2 diabetes mellitus: systematic review and meta-analysis of randomized controlled trials.meta-analysisPermalink
  12. Fasting blood glucoseMoved: lowersEffect, as reportedMD−2.17[−3.69 to −0.65]Evidence: ModeratePaper: PMID 343718672021
    Who
    Adults in randomized controlled trials of folic acid supplementation (pooled, 24 studies)
    Dose studied
    not reported

    Results revealed significant reductions in FBG (weighted mean difference (WMD): -2.17 mg/dL, 95% CI: -3.69, -0.65, p = 0.005), fasting insulin (WMD: -1.63 pmol/L, 95% CI: -2.53, -0.73, p < 0.001), and HOMA-IR (WMD: -0.40, 95% CI: -0.70, -0.09, p = 0.011) following folic acid supplementation.”

    Quoted verbatim from Folic Acid Supplementation Improves Glycemic Control for Diabetes Prevention and Management: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials.meta-analysisPermalink

No dose is advised.

  • OR odds ratio · RR risk ratio · HR hazard ratio · SMD standardised mean difference · MD mean difference. Brackets: the interval as reported.
  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed
  • Industry funding: named on its row.

04 · identity

Structure

Charge
0
2D depiction
None stored
SMILES
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2n1

05 · figures · 1 plate

Plates

  • A dial of hairlines, each a peak of folic acid's measured mass spectrum, its angle the peak's mass-to-charge ratio and its length the peak's intensity.
    fig. 4Folic acid · MS [M+H]+ LC-ESI-QQQ positive · MassBank MSBNK-RIKEN_NPDepo-CB000144 (Nogawa T, CC BY)

06 · reach

What it touches on the way

15 entities · assembled from reference reactions

  1. DHFRProtein93 paths · 31 endpointsinferred
  2. ABCC5Protein22 paths · 11 endpointsinferred
  3. DHFR2Protein15 paths · 5 endpointsinferred
  4. ABCC2Protein15 paths · 15 endpointsinferred
  5. ABCG2Protein14 paths · 14 endpointsinferred
  6. ABCC4Protein10 paths · 10 endpointsinferred
  7. FOLR1Protein5 paths · 5 endpointsinferred
  8. SLC19A1Protein4 paths · 2 endpointsinferred
  9. SLC46A1Protein4 paths · 2 endpointsinferred
  10. SLCO1B1Protein3 paths · 2 endpointsinferred
  11. ABCC1Protein2 paths · 2 endpointsinferred
  12. SLC22A7Protein2 paths · 2 endpointsinferred
Show the remaining 3Show the first 12Every entity, on one page

Where it reaches

12 regions · transporter routes

  1. Small intestinedigestive4 routesinferred
  2. Brainnervous3 routesinferred
  3. Eyenervous3 routesinferred
  4. Liverdigestive3 routesinferred
  5. Colon and rectumdigestive2 routesinferred
  6. Female reproductivereproductive2 routesinferred
  7. Male reproductivereproductive2 routesinferred
  8. Mouth and oesophagusdigestive2 routesinferred
  9. Skeletal musclemusculoskeletal2 routesinferred
  10. Blood vesselscardiovascular1 routeinferred
  11. Bone and jointmusculoskeletal1 routeinferred
  12. Gallbladderdigestive1 routeinferred

07 · documented · reference

Interactions

Documented interactions
None reported

Pairs that share biology

What the reference databases state

Reference statements
3101 ProteinABCC1, ABCC2, ABCC4, ABCC5, ABCG2, FOLR1, and 11 more02 Compound7,8-dihydrofolateinferred, one hop from folic acid
Reactions · Rhea
17reactions
31Reference statements

What the reference databases state

Evidence key

Statements

31 statements

Sources: Human-GEM, Rhea

1876folic acid31 STATEMENTS
Show the remaining 7Show the first 12
17Reactions

08 · on the label · 8,953 products

Labelled products

Source: NIH DSLD · Ingredient: folic acid · 8,953 products · Declared amount per serving (the first 1,000 shown): 1.5–800,000 µg

963 labels of the first 1,000 shown state an amount37 do not

  • 1st PhormM-Factor Hero600 µgper 3 capsulesDSLD:12881
  • 21st CenturyDiabetic Support Formula800 µgper 3 tabletsDSLD:11189
  • 21st CenturyOne Daily Active400 µgper 1 tabletDSLD:11548
  • 21st CenturyOne Daily Adults 50+400 µgper 1 tabletDSLD:11549
  • 21st CenturyOne Daily Cholesterol Health With Policosanol400 µgper 1 tabletDSLD:11550
  • 21st CenturyOne Daily Energy400 µgper 1 tabletDSLD:11552
  • 21st CenturyOne Daily Essential400 µgper 1 tabletDSLD:11556
  • 21st CenturyOne Daily Maximum400 µgper 1 tabletDSLD:11558
  • 21st CenturyOne Daily Men's Health400 µgper 1 tabletDSLD:11559
  • 21st CenturyOne Daily Weight Control400 µgper 1 tabletDSLD:11560
  • 21st CenturyOne Daily Women's400 µgper 1 tabletDSLD:11561
  • 21st CenturyOne Daily Women's 50+400 µgper 1 tabletDSLD:11497
Show the remaining 8,941Show the first 12

Label record: NIH Office of Dietary Supplements · CC0

09 · the record

Sources

2,594

papers screened for folic acid

admitted
23
read and discarded
1,145
not read yet
1,426

The screening record, every paper and why